Compugen
- Country
- Ownership
- -
- Employees
- 68
- Market Cap
- -
- Introduction
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
- Conditions
- Ovarian CancerOvarian Cancer Recurrent
- Interventions
- Drug: Normal Saline
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06888921
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
A Clinical Trial to Assess COM503 in Participants with Advanced Solid Malignancies
- Conditions
- NeoplasmCancer, Malignant Tumors
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06759649
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸NEXT Oncology San Antonio, San Antonio, Texas, United States
🇺🇸START, San Antonio, Texas, United States
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
- Conditions
- Endometrial NeoplasmsSolid TumorOvarian CancerHead and Neck Cancer
- Interventions
- Drug: COM701 in combination with BMS-986207 and nivolumab.
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT04570839
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸The University of Tennessee WEST Cancer Center., Memphis, Tennessee, United States
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
- Conditions
- HNSCCMSS-CRCAdvanced CancerLung CancerOvarian CancerColon CancerMultiple MyelomaMicrosatellite Stable Colorectal CarcinomaPlasma Cell Neoplasm
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT04354246
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸The Ohio State University Comprehensive Cancer Center., Columbus, Ohio, United States
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
- Conditions
- Advanced CancerOvarian CancerBreast CancerLung CancerEndometrial CancerOvarian NeoplasmTriple Negative Breast CancerLung NeoplasmNeoplasm MalignantColo-rectal Cancer
- Interventions
- Drug: COM701 with Opdivo (Nivolumab).
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Compugen Ltd
- Target Recruit Count
- 121
- Registration Number
- NCT03667716
- Locations
- 🇺🇸
University of California Los Angeles (UCLA)., Los Angeles, California, United States
🇺🇸M D Anderson Cancer Center., Houston, Texas, United States
🇺🇸The START Center for Cancer Care., San Antonio, Texas, United States